No clear cardio benefits were observed in a trial on nearly 15,000 male physicians taking multivitamin or placebo.
New analysis is available from the Physicians’ Health Study (PHS) II, a “gold standard” trial on nearly 15,000 male U.S. physicians taking multivitamin or placebo for over 10 years. This time, findings relate to multivitamin use and heart health.
Writing in the Journal of the American Medical Association (JAMA), researchers from Harvard Medical School and the Brigham and Women’s Hospital in Boston determined that “taking a daily multivitamin did not reduce major cardiovascular events,” including heart attack, stroke, and death by heart disease. Per 1000 person-years, multivitamin users experienced one slightly reduced risks of each condition compared to placebo.
“We’re not surprised by these results, but they don’t discount the many other benefits that multivitamins provide, including filling nutrient gaps, helping prevent neural tube birth defects, and serving in combination with other healthy habits as a basic and affordable insurance policy for overall wellness,” said Duffy MacKay, ND, vice president of scientific and regulatory affairs at CRN. “Even though two weeks ago this same study demonstrated a modest but significant reduction in total cancer risk in this same population, no one should expect the multivitamin to wipe out all diseases known to man.”
The Physicians’ Health Study II was supported by National Institutes of Health grants.
Sirio Pharma launches line of ready-to-market organic gummies and softgels called PureOrganix
August 26th 2024The new line is made up of three gummies and one softgel that are formulated to meet stringent EU-Organic certification criteria, and target women’s health, metabolic health, and heart health.
SourceOne Global Partners to distribute Qualitas Health’s microalgae omega-3 ingredient globally
August 15th 2024SourceOne Global Partners has announced a partnership with Qualitas Health Inc., (dba iwi life) to introduce the company’s trademarked AlmegaPL microalgae omega-3 ingredient to the global marketplace.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.